

RESEARCH ARTICLE

Enhanced biofilm and extracellular matrix production by chronic carriage versus acute isolates of *Salmonella* TyphiAishwarya Devaraj¹, Juan F. González^{1,2,3}, Bradley Eichar^{1,2}, Gatan Thilliez⁴, Robert A. Kingsley^{4,5}, Stephen Baker^{6,7}, Marc W. Allard⁸, Lauren O. Bakaletz^{1,3,9}, John S. Gunn^{1,2,3,9,10*}, Steven D. Goodman^{1,3,9,10*}

1 Center for Microbial Pathogenesis, Research Institute at Nationwide Children's Hospital, Columbus, Ohio, United States of America, **2** Department of Microbial Infection and Immunity, The Ohio State University, Columbus, Ohio, United States of America, **3** Department of Pediatrics, College of Medicine, The Ohio State University, Columbus, Ohio, United States of America, **4** Quadram Institute Bioscience, Norwich, United Kingdom, **5** University of East Anglia, Norwich, United Kingdom, **6** Cambridge Institute of Therapeutic Immunology and Infectious Disease, University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, Cambridge, United Kingdom, **7** Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, Cambridge, United Kingdom, **8** Food and Drug Administration-FDA, College Park, Maryland, United States of America, **9** Infectious Diseases Institute, The Ohio State University, Columbus, Ohio, United States of America, **10** Oral and GI Microbiology Research Affinity Group, Nationwide Children's Hospital, Columbus, Ohio, United States of America

* John.Gunn@NationwideChildrens.org (JSG); Steven.Goodman@NationwideChildrens.org (SDG)
 OPEN ACCESS

Citation: Devaraj A, González JF, Eichar B, Thilliez G, Kingsley RA, Baker S, et al. (2021) Enhanced biofilm and extracellular matrix production by chronic carriage versus acute isolates of *Salmonella* Typhi. *PLoS Pathog* 17(1): e1009209. <https://doi.org/10.1371/journal.ppat.1009209>

Editor: Andreas J. Baumler, University of California Davis School of Medicine, UNITED STATES

Received: October 13, 2020

Accepted: December 2, 2020

Published: January 19, 2021

Peer Review History: PLOS recognizes the benefits of transparency in the peer review process; therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. The editorial history of this article is available here: <https://doi.org/10.1371/journal.ppat.1009209>

Copyright: This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the [Creative Commons CC0](https://creativecommons.org/licenses/by/4.0/) public domain dedication.

Data Availability Statement: All relevant data are within the manuscript and its [Supporting Information](#) files.

Abstract

Salmonella Typhi is the primary causative agent of typhoid fever; an acute systemic infection that leads to chronic carriage in 3–5% of individuals. Chronic carriers are asymptomatic, difficult to treat and serve as reservoirs for typhoid outbreaks. Understanding the factors that contribute to chronic carriage is key to development of novel therapies to effectively resolve typhoid fever. Herein, although we observed no distinct clustering of chronic carriage isolates via phylogenetic analysis, we demonstrated that chronic isolates were phenotypically distinct from acute infection isolates. Chronic carriage isolates formed significantly thicker biofilms with greater biomass that correlated with significantly higher relative levels of extracellular DNA (eDNA) and DNABII proteins than biofilms formed by acute infection isolates. Importantly, extracellular DNABII proteins include integration host factor (IHF) and histone-like protein (HU) that are critical to the structural integrity of bacterial biofilms. In this study, we demonstrated that the biofilm formed by a chronic carriage isolate *in vitro*, was susceptible to disruption by a specific antibody against DNABII proteins, a successful first step in the development of a therapeutic to resolve chronic carriage.

Author summary

Salmonella Typhi, a human restricted pathogen is the primary etiologic agent of typhoid fever, an acute systemic infection that has a global incidence of 21 million cases annually. Although the acute infection is resolved by antibiotics, 3–5% of individuals develop

Funding: This work was supported by NIH grant R01DC011818 to SDG and LOB; NIH grant R01 AI116917 and start-up funds from Abigail Wexner Research Institute at Nationwide Children's Hospital to JSG; Wellcome senior research fellowship 215515/Z/19/Z to SB; BBSRC Institute Strategic Programme Microbes in the Food Chain BB/R012504/1 and its constituent projects BBS/E/F/000PR10348 and BBS/E/F/000PR10349 to RAK. The funders did not play any role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: The authors have declared that no competing interests exist.

chronic carriage that is difficult to resolve with antibiotics. A majority of these individuals serve as reservoirs for further spread of the disease. Understanding the differences between acute and chronic carrier strains is key to design novel targeted approaches to undermine carriage. Here, we demonstrated that chronic carrier strains although not genotypically distinct from acute strains, formed thicker biofilms with greater relative levels of extracellular eDNA and DNABII proteins than those formed by acute infection isolates. We also demonstrated that an antibody against DNABII proteins significantly disrupted biofilms formed by a chronic carrier strain and therefore supported development of therapeutic use of this antibody to attenuate chronic carriage.

Introduction

Salmonella enterica is a facultative intracellular, Gram-negative gammaproteobacterium, which is classified into six subspecies that are further subtyped into more than 2000 serovars or serotypes based on the expression of surface antigens [1,2]. In humans, *S. enterica* serovars cause non-typhoidal [3] and typhoidal [4] illness that results in significant morbidity and mortality worldwide. Non-typhoidal *S. enterica* causes gastroenteritis with a global burden of 93 million cases and 155,000 deaths annually [5]. *Salmonella enterica* serovar Typhi (*S. Typhi*) is a human-restricted pathogen and the primary etiologic agent of typhoid fever with an incidence of 21 million cases each year that results in 200,000 deaths annually [6].

Enteric or typhoid fever is an acute systemic infection that is commonly caused by poor sanitation and the consumption of contaminated food or water [7]. Although acute infections are resolved by treatment with antibiotics, a high incidence of antibiotic resistance with about 60% of strains that exhibit multidrug resistance, exacerbates the morbidity and mortality, particularly, within typhoid endemic regions [8]. Most importantly, 3–5% of the individuals with an acute infection ultimately develop chronic asymptomatic carriage in the gallbladder [9]. This chronic carriage state not only serves as a reservoir for further spread of the disease via bacterial shedding in feces, but is also difficult to resolve with antibiotics [10–13]. Given the grave public health concern of both acute infections and chronic carriage of *S. Typhi*, it is important to understand the development of each of these states to design and test targeted approaches to resolve the more recalcitrant chronic carriage.

The hallmark of chronic carriage of *S. Typhi* is the successful colonization of the gallbladder and biofilm formation on the surface of gallstones [14,15]. Biofilms are organized three-dimensional multicellular communities encased in self-produced extracellular polymeric substances (EPS) that is comprised of polysaccharides, extracellular DNA [eDNA], proteins and lipids [16,17]. Biofilm formation on the surface of gallstones is thought to protect the resident bacteria from the harsh environment within the gallbladder (e.g. presence of bile), host immune effectors, and antibiotics [18]. Although the negative impact of the chronic carriage state on human health has been recognized for over a century, very little is known about the genotypic and phenotypic differences between acute infection and chronic carriage isolates of *S. Typhi*.

In order to better characterize the differences in phenotypic and genotypic characteristics of acute infection and chronic carriage isolates of *S. Typhi*, in this study, we sequenced a lab strain *S. Typhi* Ty2 (JSG698), and multiple acute infection (14 isolates from patients with an acute infection) and chronic carriage isolates (6 isolates from chronic carriers). We also examined the ability of each of these isolates to form biofilms *in vitro* (as biofilm formation is a hallmark of chronic carriage) and compared the relative levels of multiple EPS components

(eDNA, DNABII proteins and lipopolysaccharides [19,20]) within their respective biofilms to determine if these correlated with differences in the magnitude of the biofilms formed. Perhaps most importantly, we have also shown that *S. Typhi* biofilms, similar to those formed by 22 single and multi-species bacterial biofilms, incorporate DNABII proteins that stabilize the eDNA lattice-like structure [21–24]. Sequestration of DNABII proteins from bacterial biofilm via specific antibodies, results in collapse of the EPS which causes release of biofilm-resident bacteria that are highly sensitive to antibiotics and immune factors [21,22,25–30].

In this study, we demonstrated that chronic carriage isolates formed thicker biofilms than acute infection isolates and further, that of those components tested, the increase in biofilm formation by chronic carriage isolates correlated only with greater steady state levels of eDNA and DNABII proteins within the biofilm EPS. Overall, these data suggested that during carriage, chronic *S. Typhi* isolates may undergo pathoadaptation in the gallbladder for enhanced biofilm capabilities. Indeed, we also demonstrated that we could disrupt biofilms formed by chronic carriage isolates with a specific antibody that targets the DNABII proteins which thereby supported development of therapeutic use of this antiserum to potentially attenuate the chronic carriage of *S. Typhi*.

Results

Molecular and genetic typing of acute and chronic *S. Typhi* strains

To infer the phylogenetic relationship of acute and chronic *S. Typhi* isolates from Ohio, Mexico City, and Vietnam (Table 1), we determined the whole-genome sequence using short read sequence technology. A total of 1,777 single nucleotide polymorphisms in the core genome with reference to *S. Typhi* Ty2 (AE014613) were used to construct a maximum-likelihood phylogenetic tree (Fig 1A) in the context of 1909 global *S. Typhi* isolates reported previously [31]. The study isolates were widely distributed within the global diversity of *S. Typhi* and ten isolates were of the H58 haplotype that constitute the currently dominant global pandemic clade [32]. Clinical isolates displayed high genetic similarity with multiple clades formed (Fig 1B), with pairwise distance ranging from 1 to 548 SNPs in the core genome (Fig 1C). However, there was no apparent clustering of the sequenced isolates by the acute *versus* chronic infection status of the patient.

Chronic carrier isolates of *S. Typhi* formed thicker biofilms than acute infection isolates

To identify any phenotypic alterations between *S. Typhi* strains isolated from acute and chronic infections, we first set out to determine the differences in biofilms formed *in vitro* by each of these strains. This is relevant as chronic carriage of *S. Typhi* is associated with biofilm formation on the surface of gallstones [14,15]. We first characterized the differences in growth of each of the *S. Typhi* strains and observed that the chronic carriage isolates (JSG3983 and JSG3984) had a significantly longer doubling time than *S. Typhi* Ty2 strain JSG698 (S1 Fig and Table 2). Of these two strains only JSG3984 eventually matched the extent of growth of *S. Typhi* Ty2 strain. Due to these two growth defects, JSG3983 was therefore the only strain eliminated from our comparative analysis. Next, we allowed various *S. Typhi* chronic carriage and acute infection isolates and the lab strains *S. Typhi* Ty2 (JSG698 and JSG4383) (Table 1) to form biofilms *in vitro*. Since the lab strain *S. Typhi* Ty2 (JSG698) is deficient in *rpoS*, a known regulator of stationary phase gene expression, an otherwise isogenic *rpoS*⁺ strain (JSG4383 [33]) was also employed. First, no significant difference in biofilm formation between the *S. Typhi* Ty2 (JSG698) and the *S. Typhi* Ty2 *rpoS*⁺ strain (JSG4383) was observed

Table 1. Strains used in this study.

Laboratory strains				
Strain	Characteristics		Source	
JSG698	S. Typhi Ty2; wild-type		ATCC	
JSG4383	S. Typhi Ty2 <i>rpoS</i> ⁺		[35]	
JSG1213	S. Typhi Ty2 <i>tviB</i> ::Kan		Gift of Popoff lab, Pasteur Institute [34]	
JSG210	S. Typhimurium 14028s; wild-type		ATCC	
Clinical Isolates				
Strain	Isolation source/characteristics	Infection type	Country of origin	Source
JSG691 (ICOPHAI17078)	Blood	Acute	USA	University of Texas Health Science Center at San Antonio
JSG3074 (ICOPHAI17076)	Gallstone	Chronic	Mexico	General Hospital of Mexico, Mexico City
JSG4123	JSG3074 Δ <i>tviB</i> via Wanner	NA	NA	This study
JSG3076 (ICOPHAI17077)	Gallstone	Chronic	Mexico	General Hospital of Mexico, Mexico City
JSG3395 (ICOPHAI17081)	Blood	Acute	USA	Ohio Department of Health
JSG3400 (ICOPHAI17086)	Bile	Acute	USA	Ohio Department of Health
JSG3407 (ICOPHAI17082)	Stool	Acute	USA	Ohio Department of Health
JSG3418 (ICOPHAI17085)	Stool	Acute	USA	Ohio Department of Health
JSG3419 (ICOPHAI17083)	Blood	Acute	USA	Ohio Department of Health
JSG3431 (ICOPHAI17084)	Stool	Acute	USA	Ohio Department of Health
JSG3433 (ICOPHAI17079)	Blood	Acute	USA	Ohio Department of Health
JSG3441 (ICOPHAI17080)	Stool	Acute	USA	Ohio Department of Health
JSG3979 (GB169)	Gallbladder	Chronic	Vietnam	Gift of S. Baker
JSG3980 (GB281)	Gallbladder	Chronic	Vietnam	Gift of S. Baker
JSG3981 (GB31)	Gallbladder	Chronic	Vietnam	Gift of S. Baker
JSG3982 (GB335)	Gallbladder	Chronic	Vietnam	Gift of S. Baker
JSG3983 (GB266)	Gallbladder	Chronic	Vietnam	Gift of S. Baker
JSG3984 (GB26)	Gallbladder	Chronic	Vietnam	Gift of S. Baker
JSG3985 (TY421)	Unspecified	Acute	Vietnam	Gift of S. Baker
JSG3986 (TY312)	Unspecified	Acute	Vietnam	Gift of S. Baker
JSG3987 (TY311)	Unspecified	Acute	Vietnam	Gift of S. Baker
JSG3988 (TY102)	Unspecified	Acute	Vietnam	Gift of S. Baker
JSG3989 (TY261)	Unspecified	Acute	Vietnam	Gift of S. Baker
JSG3990 (TY96)	Unspecified	Acute	Vietnam	Gift of S. Baker

NA = Not applicable.

<https://doi.org/10.1371/journal.ppat.1009209.t001>

as evidenced by biofilm average thickness (Fig 2A) and biofilm biomass (Fig 2B). This result suggested that the lack of *rpoS* had no significant effect on biofilm formation by the *S. Typhi* Ty2 strain JSG698.

As shown in Fig 2, when grossly assessed, while 5 out of the 6 chronic carriage isolates (83%) formed significantly thicker biofilms as compared to the lab strain *S. Typhi* Ty2 (JSG698), only 2 out of the 14 acute infection isolates (14%) formed significantly thicker biofilms as compared to lab strain. Next, we determined the average thickness and biomass of biofilms formed by chronic (indicated by the red dotted line labeled AC) versus acute infection isolates (indicated by the blue dotted line labeled AA). In general, chronic carriage isolates formed significantly thicker biofilms ($P < 0.01$) with greater biomass ($P < 0.01$) compared to those formed by acute infection isolates (Fig 2). To further validate our confocal microscopy-based analyses, we enumerated the bacteria within each biofilm (adherent state) and demonstrated that in biofilms formed by chronic carriage isolates, on average 52.5% of the




Fig 1. Phylogenetic relationship of *S. Typhi* isolates. (A) Maximum likelihood phylogenetic tree based on core genome sequence variation. This shows the relationship of *S. Typhi* strains used in this study in the context of a global collection of *S. Typhi* strains reported in (31). (B) Maximum likelihood phylogenetic tree showing the relationship of *S. Typhi* clinical isolates and *S. Typhi* Ty2 based on core genome sequence variation. (C) Single nucleotide polymorphism distance matrix and heatmap of isolates in this study. There was no apparent clustering of the sequenced isolates by the acute *versus* chronic infection status of the patient.

<https://doi.org/10.1371/journal.ppat.1009209.g001>

total bacteria were in the biofilm state, whereas this value was 26.8% for biofilms formed by acute infection isolates (S2 Fig). These data were consistent with our analysis derived via confocal microscopy and collectively suggested that chronic carriage isolates were significantly different from acute infection isolates in their relative ability form biofilms, *in vitro*.

Chronic carriage isolates yielded higher steady state levels of eDNA and DNABII proteins within their biofilm EPS compared to those formed by acute infection isolates

Given that chronic carriage isolates formed a thicker biofilm with greater biomass as compared to those formed by acute infection isolates, we examined the steady state levels of various EPS components within *S. Typhi* biofilms to correlate with the differences in biofilm architecture observed between chronic carriage and acute infection isolates. *S. Typhi* whole cells (WC; extracellular) or cell lysates (Ly) were blotted on PVDF membranes and probed with either α -Vi-antigen (S3A Fig) or α -O9 O-antigen of the LPS (S3B Fig) antibodies. As shown in S4 Fig,

Table 2. Doubling time in hours for each of the indicated *S. Typhi* strains.

Strain	Doubling time (hours)
<i>S. Typhi</i> Ty2 (JSG698)	1.19 ± 0.01
JSG3395	1.14 ± 0.01
JSG3407	1.21 ± 0.01
JSG3418	1.20 ± 0.01
JSG3419	1.20 ± 0.01
JSG3431	1.23 ± 0.02
JSG3433	1.16 ± 0.02
JSG3441	1.17 ± 0.01
JSG3985	1.21 ± 0.004
JSG3986	1.24 ± 0.01
JSG3987	1.26 ± 0.01
JSG3988	1.24 ± 0.004
JSG3989	1.15 ± 0.01
JSG3990	1.20 ± 0.01
JSG3074	1.21 ± 0.005
JSG3979	1.20 ± 0.02
JSG3980	1.25 ± 0.02
JSG3981	1.19 ± 0.01
JSG3982	1.23 ± 0.01
JSG3983	1.36 ± 0.02 ****
JSG3984	1.33 ± 0.02 ****

Statistical significance of doubling times for each of the chronic carriage or acute infection strain versus the *S. Typhi* Ty2 strain, JSG698 was assessed by a one-way ANOVA followed by Dunnett's multiple comparison test.

****P<0.0001.

<https://doi.org/10.1371/journal.ppat.1009209.t002>

while Vi-antigen was variably expressed by both chronic carriage and acute infection isolates, no characteristic pattern of expression was observed for either group (S3A Fig). *S. Typhimurium* strain 14028s and *S. Typhi tviB::Kan* [34] served as negative controls. O9 antigen was below the level of detection in WC blots of multiple chronic carriage and acute infection isolates. Additionally, no apparent difference in the expression of O9 antigen was observed between chronic carriage and acute infection isolates (S3B Fig). *S. Typhimurium* strain 14028s served as a negative control in these latter blots. These data suggested that chronic carriage isolates had no discernible pattern of differences from acute infection isolates with respect to the expression of either O9 antigen or Vi-antigen.

Next, we quantified the relative extracellular levels of eDNA and DNABII proteins within the biofilms formed by the indicated *S. Typhi* strains. We allowed biofilms to be formed by each strain for 40 hours, then incubated the biofilms with α -dsDNA monoclonal antibody and α -IHF_{Ec} (recognizes both IHF and HU isolated from a large crossection of bacterial species; also the primary amino acid sequences of IHF and HU from *E. coli* and *Salmonella* are identical) to visualize both eDNA and DNABII proteins within the biofilm EPS by immunofluorescence microscopy (IF). The bacterial membrane stain, FM 4–64 was used to designate the overall biofilm architecture. The distribution of eDNA (teal) and DNABII proteins (purple) within the biofilm EPS of representative chronic carriage (JSG3980) and acute infection (JSG3986) isolates compared to lab strain *S. Typhi* Ty2 (JSG698) is shown in Fig 3A. The fluorescence intensity of eDNA (Fig 3B) and DNABII proteins (Fig 3D) were quantified, and the average fluorescence intensity of eDNA and DNABII proteins within the EPS of biofilms




Fig 2. Chronic carriage isolates formed thicker biofilms than acute isolates. Biofilms of each of the indicated *S. Typhi* strains were established in a 8-well chambered coverglass slide for 40 hours. Biofilms were stained with LIVE/DEAD stain and visualized via CLSM. Images were analyzed by COMSTAT to calculate average thickness (A) and biomass (B). Bars represent the standard error of the mean (SEM). The mean of the average thickness or biomass of the chronic carriage isolates was represented by the red dotted line labeled AC and the mean of the average thickness or biomass of the acute isolates was represented by the blue dotted line labeled AA. Statistical significance of average thickness or biomass of each of the strains versus the lab strain, *S. Typhi* Ty2 (JSG698), was assessed by a one-way ANOVA followed by Dunnett’s multiple comparison test. Statistical significance between AC and AA were assessed by a one-way ANOVA followed by Tukey’s multiple comparison test. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, **** $P < 0.0001$. On average, chronic carriage isolates formed a thicker biofilm with more biomass than acute isolates. Chronic carriage isolates are indicated in red and acute infection isolates are indicated in blue.

<https://doi.org/10.1371/journal.ppat.1009209.g002>

formed by acute infection and chronic carriage isolates was represented by the blue and red dotted lines labeled AA and AC respectively. As shown in Fig 3B and 3D, on average, chronic carriage isolates had significantly higher steady state levels of both eDNA ($P < 0.01$) and DNABII proteins ($P < 0.01$) within their biofilm EPS as compared to acute infection isolates. However, despite the greater absolute abundance of eDNA and DNABII proteins within biofilms formed by chronic carriage isolates, the relative abundance of eDNA and DNABII proteins [as determined by the ratio of fluorescence intensity of eDNA or DNABII proteins to the fluorescence intensity of bacteria] was not different (see dotted lines AC and AA in Fig 3C and 3E).

Thus, regardless of biofilm size, the ratio of eDNA and DNABII to the number of cells in the biofilm remains constant. This result suggested that in order for biofilms to incorporate bacterial cells they are rate limited by constant ratios of eDNA and DNABII i.e. the more eDNA and DNABII present within the biofilms, the more bacteria they can incorporate. Collectively, these data suggested that while chronic carriage and acute infection isolates did not have a discernible difference in expression of either LPS or Vi-antigen, the relative amount of eDNA and DNABII proteins were significantly greater within biofilms formed by chronic carriage isolates than that within the biofilms formed by acute infection isolates due to the presence of more bacteria.

Biofilms formed by *S. Typhi* were disrupted upon incubation with a DNABII-specific antibody

DNABII proteins serve as linchpin proteins to stabilize the eDNA lattice structure and in turn, sequestration of DNABII proteins from the biofilm EPS with specific antibodies results in significant disruption of single and multi-species biofilms *in vitro*, *ex vivo* and *in vivo* [21,22,24–27,29,30,35–37]. Accordingly, we hypothesized that the greater the steady state levels of DNABII proteins present within a biofilm, the greater the dose of DNABII-directed antibodies that would be required for biofilm disruption. Since biofilms formed by chronic carriage isolates




Fig 3. Chronic carriage isolates have higher steady levels of extracellular DNA and DNABII proteins within their biofilm EPS than acute isolates. Biofilms of each of the indicated *S. Typhi* strains were established in an 8-well chambered coverglass slide for 40 hours. Biofilms were labeled with α -dsDNA monoclonal antibody, α -IHF_{Ec} and FM 4–64 and visualized via CLSM. (A) Representative immunofluorescence images of a lab wild type strain *S. Typhi* Ty2 (JSG698), chronic carriage isolate (JSG3980) and acute isolate (JSG3986). eDNA is visualized in teal and DNABII proteins in purple. Images were analyzed by ImageJ to quantify the fluorescence intensity of eDNA (B), DNABII proteins (D), and bacteria. Fluorescence intensity of eDNA and DNABII proteins were normalized to cells and plotted in (C) and (E), respectively. Bars represent the SEM. AA and AC represent the averages of acute infection isolates and chronic carriage isolates, respectively. Statistical significance between AC and AA were assessed by a one-way ANOVA followed by Tukey’s multiple comparison test. ** $P < 0.01$. On average, chronic carriage isolates had higher steady state levels of both eDNA and DNABII proteins within the biofilm EPS as compared to acute isolates. Chronic carriage isolates are indicated in red and acute infection isolates are indicated in blue.

<https://doi.org/10.1371/journal.ppat.1009209.g003>

had a greater amount of DNABII proteins, here we wanted to determine if these could nonetheless be disrupted with specific antibodies. To this end, we allowed the lab strain *S. Typhi* Ty2 (JSG698) and the chronic carriage isolate (JSG3074; used here as a representative bacterium) to form biofilms for 24 hours, then incubated these biofilms with α -IHF_{Ec}, for 16 hours. Naive IgG was used as a negative control. As shown in Fig 4, biofilms formed by both the lab strain and the chronic carriage isolate were significantly disrupted by α -IHF_{Ec} (significant decrease in biomass as compared to naive IgG), although as hypothesized, a greater




Fig 4. DNABII-specific antibody disrupted biofilms formed by chronic carriage isolate of *S. Typhi*. (A) Biofilms formed by lab wild type strain *S. Typhi* Ty2 (JSG698) or chronic carriage isolate (JSG3074) or (B, C) JSG698 were established in an 8-well chambered coverglass slide in TSB (A), chambered coverglass slide coated with 5 mg/ml cholesterol (B), or TSB+0.5% ox bile extract (C) for 24 hours. Biofilms were incubated with medium alone, naive IgG, or α -IHF_{Ec} IgG at the indicated concentration for 16 hours. Biofilms were stained with LIVE/DEAD stain and visualized via CLSM. Images were analyzed by COMSTAT to calculate biomass. Bars represent the SEM. ** $P < 0.01$, *** $P < 0.001$ via unpaired *t* test. Biofilms formed by *S. Typhi* Ty2 (JSG698) in the presence of cholesterol and bile, as well as a chronic carriage isolate of *S. Typhi*, were significantly disrupted by DNABII-specific antibody (α -IHF_{Ec}).

<https://doi.org/10.1371/journal.ppat.1009209.g004>

concentration of α -IHF_{Ec} was required to achieve a similar effect in the biofilm formed by the chronic carriage isolate as that observed for the lab strain. This requirement for a greater concentration of α -IHF_{Ec} for biofilm disruption was consistent with the presence of higher steady state levels of DNABII proteins within biofilm EPS of the chronic carriage isolate as compared to the lab strain (Fig 3).

Since *S. Typhi* attaches to gallstones (that primarily consists of cholesterol) and encounters bile in the gallbladder during establishment of a chronic carriage state, and that bile induces biofilm formation of *S. Typhi* [15], we also determined the efficacy of biofilm disruption by α -IHF_{Ec} in the presence of cholesterol or bile. Biofilms formed by *S. Typhi* Ty2 strain were disrupted by α -IHF_{Ec} as observed by a significant reduction in biofilm biomass as compared to naive IgG in the presence of either cholesterol (chambered coverglass slide was coated with cholesterol to mimic the surface of gallstones) or 0.5% bile (Fig 4B and 4C). Although bile significantly increased the biomass within the biofilms formed by the lab strain with a concomitant increase in the expression of DNABII proteins both intracellularly (S4A Fig) as well as that incorporated within the biofilm EPS (S4B and S4C Fig), a greater concentration of α -IHF_{Ec} (500 $\mu\text{g/ml}$) nevertheless disrupted biofilms formed under conditions designed to mimic those within the gallbladder. Collectively, these results suggested that the biofilms formed by chronic carriage isolates were susceptible to disruption by α -IHF_{Ec} *in vitro* (albeit at a higher α -IHF_{Ec} concentration), an essential first step to develop these antibodies as a therapeutic that can potentially resolve chronic carriage of *S. Typhi*.

Discussion

The chronic carriage state of *S. Typhi* is difficult to treat and these individuals also serve as reservoirs that can cause community outbreaks of typhoid fever. A more comprehensive characterization of the differences between acute infection and chronic carriage isolates is critical in order to understand the development of the chronic carriage state and design novel, specific targeted approaches to undermine carriage.

In this study, we first characterized the genotypic and phenotypic differences between acute infection and chronic carriage isolates of *S. Typhi* and demonstrated that each of these strains were widely distributed within the global diversity of *S. Typhi* strains with no evident clustering. Although large-scale rearrangements between ribosomal RNA operons have been documented in longitudinal isolates of an *S. Typhi* strain from a chronic carrier [38], our sequence analysis of multiple acute infection and chronic carriage isolates from various geographical locations suggested no distinct clustering of strains based on the chronic carrier versus acute infection status of the patient. Previous genome sequence comparison analysis of longitudinal isolates of persistent *S. Typhimurium* revealed several SNPs in global virulence regulatory genes such as *rpoS*, *dksA*, *melR* etc., that can cause pleiotropic changes in the transcription of genes during persistence [39]. Also, acquisition of mobile genetic elements has been documented during persistence that is directly attributed to the antibiotic resistant phenotype of chronic carriage isolates [38]. Thus, while in our study clustering of the acute infection versus chronic isolates does not occur, genetic events do occur in the gallbladder environment that likely affect strain phenotypes.

In contrast, we demonstrated that on average, chronic carriage isolates formed thicker biofilms than acute isolates. This result is in line with previous findings which suggest that the chronic carriage state of *S. Typhi* is facilitated by formation of biofilms on gallstones within the gallbladder wherein *S. Typhi* predominantly persists [14,15]. Biofilm resident bacteria are highly recalcitrant to antibiotic therapy, and clearance by host immune effectors (reviewed in [40]), which in turn, facilitates chronic carriage. Much of this resistance is associated with the EPS components within biofilms, which in addition to maintenance of the biofilm structure, also provides a physical barrier to and directly compromises the activities of host immune effectors [16]. eDNA is a key structural component of bacterial biofilms [41–44] and is also incorporated within *S. Typhimurium* biofilms wherein it facilitates resistance to antibiotics and antimicrobial peptides [45]. In this study, we have shown that the thicker biofilms of chronic carriage isolates correlated with a greater relative level of eDNA than acute infection isolates that could also likely contribute to their recalcitrance to treatment modalities.

Previous studies have identified several *S. Typhi* uniquely expressed antigens from chronic carrier sera that include membrane proteins, lipoproteins and hemolysin-related proteins [46]. Additionally, persistent/chronic carriage isolates of *S. Typhi* exhibit increased expression of iron transporters and other factors that provide resistance to host antimicrobial peptides [47]. We have now identified DNABII proteins to be differentially and highly expressed within the EPS of the biofilms formed by chronic carriage isolates of *S. Typhi*. Whereas the role of this increased steady state level of eDNA and DNABII proteins, beyond their contribution to biofilm structural integrity is not yet known, a DNABII member expressed by *Mycobacteria* is known to possess ferroxidase activity. It has been suggested that ferrous iron (used for fenton chemistry to generate peroxide as a host defense) could be de-toxified by released DNABII protein-mediated oxidation to the ferric state, suitable for bacterial iron transport and utilization [48]. In addition, environmental factors such as bile within the gallbladder upregulate the expression of EPS components [49,50] that are required for biofilm formation on gallstones [20,51,52]. In line with these findings, herein we also observed that bile upregulated the intracellular expression of DNABII proteins which corresponded with a concomitant increased incorporation of these proteins into the biofilm EPS. Furthermore, the DNABII protein IHF positively regulates the expression of curli, another EPS component that contributes to biofilm formation by *S. Typhi* [53]. Collectively, our new data contribute to the findings of others to suggest that the microenvironment wherein *S. Typhi* persists results in positive regulation of components (proteins, polysaccharides etc.,) that promote the chronic carriage state.

The DNABII family of proteins are highly conserved and one of the members of the family, HU is ubiquitously expressed by eubacteria. DNABII proteins bind to and bend DNA [54,55] and thereby play a critical role in the intracellular nucleoid structure and function [56]. These proteins are also found in the EPS of multiple single and multi-species bacterial biofilms [21–24,27,30,35,57]. In this study, we now expanded upon our previous observations to demonstrate that extracellular DNABII proteins were incorporated within the EPS of biofilms formed by both acute infection and chronic carriage isolates of *S. Typhi* and that these proteins are critical to the structural integrity of biofilms formed by *S. Typhi*. These data are in line with our previous findings that DNABII proteins serve as linchpin proteins to stabilize the eDNA lattice structure and their sequestration, via incubation with a specific antibody, disrupts multiple bacterial biofilms *in vitro* [21,22,24,26,27,29,36], resolves bacterial biofilms *in vivo* [27,30,37], and dissolves sputum solids *ex vivo* [35]. Moreover, pre-incubation with the aforementioned DNABII-specific antibody reduces binding of uropathogenic *E. coli* to cultured bladder epithelial cells [58] and also, reduces survival of *Burkholderia cenocepacia* that have been phagocytized by murine cystic fibrosis macrophages [22]. Collectively, these results indicate that the extracellular presence of the DNABII family of proteins is involved in facets of pathogenesis in addition to its structural role in the EPS. Finally, here for the first time, we demonstrated that for multiple isolates of *S. Typhi*, there was a constant ratio between cells, eDNA and DNABII regardless of biofilm size. This latter finding strongly implied that eDNA and DNABII proteins, and their associated specific ratios, were rate limiting for biofilm formation and further suggested that more eDNA and DNABII within the biofilm matrix can shift the partitioning of cells from the planktonic state into the adherent biofilm state. Should this paradigm exist throughout eubacterial biofilms, it would indicate that the most likely rationale is for there to be a uniform common eDNA-DNABII-dependent EPS that exists within the biofilms formed by diverse species. Given that the DNABII proteins are universally conserved and have been well documented to stabilize bacterial biofilm structure, the ability to significantly disrupt a biofilm formed by a chronic carriage isolate with antibody directed against a DNABII protein is an exciting first step in the development of a novel therapeutic to attenuate chronic carriage of *S. Typhi*.

Materials and methods

Bacterial strains and growth conditions

Bacterial strains used in this study are listed in Table 1. All clinical *S. Typhi* isolates tested positive by Vi-antigen agglutination test before use. Strains were streaked on lysogeny broth (LB) agar plates and incubated at 37°C for 18–20 hours. Single colonies were used to start overnight (O/N) liquid cultures. Planktonic cells were grown at 37°C on a rotating drum in LB or tryptic soy broth (TSB). Antibiotics, when needed, were used at the following concentrations: chloramphenicol, 25 µg/ml; ampicillin, 50 or 100 µg/ml, kanamycin, 45 µg/ml; and streptomycin, 100 µg/ml. The deletion of *tviB* in strain JSG3074 was generated by the λ-Red mutagenesis method [59] with the following primers: upstream primer JG2934 (5'-ataaaatttagtaaggattaa-taagagtgttcggtatagtgtaggctggagctgctc- 3'), downstream primer JG2935 (5'-gtccgtagtctctg-taagccgtcatgattacaatctcaccatgaatatcctccttag- 3'), and verified with primers JG2936 (5'-tcagcgacttctgttattcaagtaagaaaggggtacgg- 3'), and JG2937 (5'-gctcctactgacggacgtgc-gaacgtctctagattatg- 3'). Antibiotic resistance markers were swapped out using pCP20 [60]. The mutant was verified via sequencing.

Molecular and genetic typing of acute and chronic *S. Typhi* strains

Clinical *S. Typhi* strains acquired from Vietnam had been previously whole-genome sequenced before use in this study. All remaining isolates were whole-genome sequenced as

part of a consortium with the U.S. Food and Drug Administration (FDA). Genomic DNA of each strain was isolated from overnight cultures using DNeasy Blood and Tissue kit (Qiagen, CA, United States). Isolates were sequenced using Illumina's MiSeq platform (Illumina, Inc., CA, United States). Sample preparation and the sequencing library was prepared using the Nextera XT Sample Preparation Kit and then sequenced for 2×250 cycles. The assembled sequences were annotated using the NCBI Prokaryotic Genomes Annotation Pipeline (PGAP) and have been deposited at DDBJ/EMBL/GenBank. Genomes are publicly available from Pathogen Detection at NCBI (search ICOPHAI IDs at <https://www.ncbi.nlm.nih.gov/pathogens/isolates/>).

The maximum-likelihood phylogenetic tree was constructed from the core SNP alignment of all isolates using snippy version 3.0 as previously described [61]. *S. Typhi* Ty 2 (JSG698) was used as a reference for the mapping and SNP calling steps. *S. Paratyphi* A (strain A270) and *S. Typhimurium* 14028s (JSG210) were included as outgroups to infer the true root for the tree in Fig 1A and 1B respectively, but were removed for mapping and variant calling and the resulting tree manually rooted. RAxML (version 8.2.10) [62] was used to construct maximum likelihood phylogenetic trees from the core SNP alignment, with the generalized time-reversible model and a Gamma distribution to model site-specific rate variation (the GTR+ Γ substitution model; GTRGAMMA in RAxML). Support for the maximum-likelihood phylogeny was assessed via 400 rapid bootstraps based on the MRE_IGN-based Bootstrapping criterion.

Visualization and quantification of biofilms formed by various *S. Typhi* strains

S. Typhi strains were cultured on TSB agar for 18–20 h at 37°C, 5% CO₂ in a humidified atmosphere, then suspended in TSB to an OD of 0.65 at 490 nm. Cultures were diluted 1:6 in TSB, then incubated statically at 37°C, 5% CO₂ until an OD of 0.6 was reached at 490 nm. The cultures were diluted 1:2500 in TSB and 200 μ l of this suspension was inoculated into each well of an eight-well chambered cover glass slide (Fisher Scientific). Slides were incubated statically for 16 h at 37°C, 5% CO₂ in a humidified atmosphere at which time, spent medium was aspirated and replaced with fresh TSB. After an additional 8 h (24 h total incubation time), spent medium was aspirated and replaced with fresh TSB. After an additional 16 h (40 h total incubation time), biofilms were stained with LIVE/DEAD *BacLight* Bacterial Viability kit for microscopy (Molecular Probes) as per manufacturer's instructions, then fixed (1.6% paraformaldehyde- 0.025% glutaraldehyde, 4% acetic acid in 0.2M phosphate buffer, pH 7.4). Biofilms were visualized via Zeiss 510 Meta-laser scanning confocal microscope and imaged with a x63 objective. Biofilm average thickness and biomass were determined by COMSTAT analysis [63]. The assay was repeated three times on separate days. Data are presented as mean \pm SEM.

Determination of the number of bacteria in the planktonic or biofilm state

Biofilms were established as described in 'Visualization and quantification of biofilms' for 40 h. Bacteria within the adherent biofilm as well as those within the culture fluid above the biofilm (e.g. planktonic state) were enumerated as described previously [57].

Dot blot assay

Bacterial cultures were grown overnight in TSB at 37°C with aeration, fixed in 4% paraformaldehyde (PFA), and normalized to OD₆₀₀ = 0.8 in PBS. Normalized cultures were then divided into a lysate group and a non-lysate group (no further processing). Lysate group was boiled for 10 min to lyse the cells. Bacterial dilutions (1:6 for Vi-antigen; 1:20 and 1:50 for O9 antigen) were prepared, and 200 μ l was spotted onto methanol-activated PVDF membranes using a

suction manifold device. The blots were dried and blocked at 4°C O/N with 5% milk buffer, followed by incubation in either α -Vi-antigen (1:1000) or α -O9 antigen (1:1000). The blots were washed 3 times, 15 minutes each, in tris-buffered saline with polysorbate 20 (TBST) and incubated with α -mouse IgG 1:2000 (for O9 antigen) or α - rabbit IgG 1:2000 (for Vi Antigen) antibodies conjugated with horseradish peroxidase (Bio- Rad) O/N at 4°C prior to visualization using the Bio-Rad Chemi-Doc XRS system.

Visualization and quantification of eDNA and DNABII proteins within the biofilm EPS of various *S. Typhi* strains

Biofilms were established as described in ‘Visualization and quantification of biofilms’ for 40 h. Unfixed biofilms were washed once with sterile PBS and incubated with either: 5 μ g/ml mouse isotype control IgG 2a; 5 μ g/ml α -dsDNA monoclonal antibody; 7.5 μ g/ml naive rabbit IgG; or 7.5 μ g/ml α -IHF_{EC} in 5% BSA in PBS for 1 h at room temperature. Biofilms were washed once with PBS and incubated with 1:200 dilution of each of goat α -mouse IgG 405, goat α -rabbit IgG 488 and FM4-64 for 1 h at room temperature. Biofilms were washed once with PBS then imaged with a x63 objective on a Zeiss 800 Meta-laser scanning confocal microscope (Zeiss). Three-dimensional images were reconstructed with AxioVision Rel 4.8 (Zeiss). Fluorescence intensity of DNABII proteins, eDNA and bacteria were quantified by ImageJ software and relative abundance of eDNA or DNABII proteins were determined by the ratio of fluorescence intensity of eDNA or DNABII proteins to the fluorescence intensity of bacteria. The assay was repeated three times on separate days. Bars represent the mean \pm SEM.

Disruption of *S. Typhi* biofilms with α -IHF_{EC}

S. Typhi strains were cultured on TSB agar for 18–20 h at 37°C, 5% CO₂ in a humidified atmosphere, then suspended in TSB to an OD of 0.65 at 490 nm. Cultures were diluted 1:6 in TSB then incubated statically at 37°C, 5% CO₂ until an OD of 0.6 was reached at 490 nm. The cultures were diluted 1:2500 in TSB or TSB supplemented with ox bile extract or human bile to 0.5%, and 200 μ l of this suspension was inoculated into each well of an eight-well chambered cover glass slide. Slides were coated with cholesterol as described [50]. Slides were incubated statically for 16 h at 37°C, 5% CO₂ in a humidified atmosphere at which time, spent medium was aspirated and replaced with fresh TSB. After an additional 8 h (24 h total incubation time), the spent medium was aspirated and replaced with fresh TSB or TSB that contained either naive IgG or α -IHF_{EC} IgG (150 μ g/ml– 500 μ g/ml). Slides were incubated statically for 16 h at 37°C, 5% CO₂ in a humidified atmosphere. Biofilms were stained and imaged as described in ‘Visualization and quantification of biofilms’.

Supporting information

S1 Fig. Characterization of planktonic growth of various *S. Typhi* strains. Exponential phase cultures of each of the indicated strains was diluted 1:1000 in TSB and incubated at 37°C with continuous shaking. Absorbance at 490 nm were measured every 15 min for 16 hours. (A) Growth curve plot of chronic carriage isolates versus the lab wild type strain *S. Typhi* Ty2 (JSG698), in triplicates. (B) Growth curve plot of acute isolates versus the *S. Typhi* Ty2 strain (JSG698), in triplicate. JSG3983 and JSG3984 were the only strains wherein a defect growth rate was observed. JSG3983 also did not grow to the same extent as *S. Typhi* Ty2 strain (JSG698). (TIF)

S2 Fig. Enumeration of bacteria within biofilms formed by various *S. Typhi* strains. Biofilms of each of the indicated *S. Typhi* strains were established on a 8-well chambered cover-glass slide for 40 hours. Biofilms were washed twice in sterile PBS, suspended in PBS, and enumerated on TSB agar. Of the total bacteria within the chambered coverglass, those that were adherent within the biofilm were enumerated and values presented as percent of total. Bars represent the SEM. The mean of the percent biofilm bacteria of the chronic carriage isolates was represented by the dotted line labeled AC and the mean of the percent biofilm bacteria of the acute infection isolates was represented by the dotted line labeled AA. Statistical significance of average thickness or biomass of each of the strains versus the *S. Typhi* Ty2 strain, JSG698 was assessed by a one-way ANOVA followed by Dunnett's multiple comparison test. Statistical significance between AC and AA were assessed by a one-way ANOVA followed by Tukey's multiple comparison test. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, **** $P < 0.0001$. On average, chronic carriage isolates had more bacteria within their biofilms than acute isolates. Chronic carriage isolates are indicated in red and acute infection isolates are indicated in blue. (TIF)

S3 Fig. Expression profile of Vi antigen and O9 antigen in various *S. Typhi* strains. Representative images of dot blots for expression of Vi antigen (A) and LPS (B). Either whole cells (WC) or cell lysates (Ly) of each of the indicated strains were spotted on methanol-activated PVDF membranes using a suction manifold device. The blots were probed with α -Vi antigen antibody (A) or α -O9 antigen antibody (B). No clear differences in the expression of Vi antigen or O9 antigen were observed between chronic carriage isolates and acute isolates. (TIF)

S4 Fig. Bile increased the expression of DNABII proteins intracellularly and increased the incorporation of DNABII proteins extracellularly within the biofilm EPS. (A) Planktonically grown *S. Typhi* Ty2 (JSG698) was pelleted, lysed and proteins were resolved on an SDS-PAGE gel. DNABII proteins were quantified by Western blot. (B) *S. Typhi* Ty2 (JSG698) biofilms were formed *in vitro* in the presence of TSB or TSB + 0.5% ox bile extract for 40 hours. Biofilms were labeled with α -IHF_{Ec} and FM 4-64 and visualized via CLSM. Representative immunofluorescence images that show the distribution of DNABII proteins within the biofilms. Images were analyzed by ImageJ to quantify the fluorescence intensity of DNABII proteins and bacteria. Fluorescence intensity of DNABII proteins (C) and fluorescence intensity of DNABII proteins normalized to cells (D) were plotted. Bars represent the SEM. * $P < 0.05$, ** $P < 0.01$ via unpaired t test. Bile increased the intracellular and extracellular steady state levels of DNABII proteins within *S. Typhi* biofilms. (TIF)

Acknowledgments

We thank Wondwossen Gebreyes for his help with genomic sequencing, Kristen Reeve for her early studies on the biofilm phenotypes of the acute and chronic isolates and John Buzzo for his comments.

Author Contributions

Conceptualization: Aishwarya Devaraj, Steven D. Goodman.

Data curation: Aishwarya Devaraj, Juan F. González, Bradley Eichar, Robert A. Kingsley, Stephen Baker, Marc W. Allard.

Formal analysis: Aishwarya Devaraj, Juan F. González, Bradley Eichar, Gatan Thilliez, Robert A. Kingsley.

Funding acquisition: Lauren O. Bakaletz, John S. Gunn, Steven D. Goodman.

Investigation: Aishwarya Devaraj, Juan F. González, Bradley Eichar.

Methodology: Aishwarya Devaraj, Bradley Eichar, Gatan Thilliez, Robert A. Kingsley.

Project administration: Robert A. Kingsley, Stephen Baker, Marc W. Allard, Lauren O. Bakaletz, John S. Gunn, Steven D. Goodman.

Resources: Robert A. Kingsley, Stephen Baker, Lauren O. Bakaletz, John S. Gunn, Steven D. Goodman.

Software: Gatan Thilliez, Robert A. Kingsley.

Supervision: Robert A. Kingsley, Stephen Baker, Marc W. Allard, Lauren O. Bakaletz, John S. Gunn, Steven D. Goodman.

Validation: Aishwarya Devaraj.

Visualization: Aishwarya Devaraj, Juan F. González, Gatan Thilliez, Robert A. Kingsley.

Writing – original draft: Aishwarya Devaraj, Gatan Thilliez, Robert A. Kingsley, Marc W. Allard.

Writing – review & editing: Juan F. González, Robert A. Kingsley, Lauren O. Bakaletz, John S. Gunn, Steven D. Goodman.

References

1. Galanis E, Lo Fo Wong DM, Patrick ME, Binsztein N, Cieslik A, Chalermchikit T, et al. Web-based surveillance and global *Salmonella* distribution, 2000–2002. *Emerg Infect Dis*. 2006; 12(3):381–8. <https://doi.org/10.3201/eid1205.050854> PMID: 16704773
2. Popoff MY, Bockemuhl J, Gheesling LL. Supplement 2002 (no. 46) to the Kauffmann-White scheme. *Res Microbiol*. 2004; 155(7):568–70. <https://doi.org/10.1016/j.resmic.2004.04.005> PMID: 15313257
3. Zhang S, Kingsley RA, Santos RL, Andrews-Polymenis H, Raffatellu M, Figueiredo J, et al. Molecular pathogenesis of *Salmonella enterica* serotype typhimurium-induced diarrhea. *Infection and immunity*. 2003; 71(1):1–12. <https://doi.org/10.1128/iai.71.1.1-12.2003> PMID: 12496143
4. Selander RK, Beltran P, Smith NH, Helmuth R, Rubin FA, Kopecko DJ, et al. Evolutionary genetic relationships of clones of *Salmonella* serovars that cause human typhoid and other enteric fevers. *Infection and immunity*. 1990; 58(7):2262–75. <https://doi.org/10.1128/IAI.58.7.2262-2275.1990> PMID: 1973153
5. Majowicz SE, Musto J, Scallan E, Angulo FJ, Kirk M, O'Brien SJ, et al. The global burden of nontyphoidal *Salmonella* gastroenteritis. *Clinical infectious diseases: an official publication of the Infectious Diseases Society of America*. 2010; 50(6):882–9. <https://doi.org/10.1086/650733> PMID: 20158401
6. Crump JA, Mintz ED. Global trends in typhoid and paratyphoid Fever. *Clinical infectious diseases: an official publication of the Infectious Diseases Society of America*. 2010; 50(2):241–6. <https://doi.org/10.1086/649541> PMID: 20014951
7. Budd W. Typhoid Fever Its Nature, Mode of Spreading, and Prevention. *Am J Public Health (N Y)*. 1918; 8(8):610–2.
8. Pratap CB, Patel SK, Shukla VK, Tripathi SK, Singh TB, Nath G. Drug resistance in *Salmonella enterica* serotype Typhi isolated from chronic typhoid carriers. *International journal of antimicrobial agents*. 2012; 40(3):279–80. <https://doi.org/10.1016/j.ijantimicag.2012.05.007> PMID: 22789724
9. Parry CM, Hien TT, Dougan G, White NJ, Farrar JJ. Typhoid fever. *N Engl J Med*. 2002; 347(22):1770–82. <https://doi.org/10.1056/NEJMra020201> PMID: 12456854
10. Johnson WD Jr., Hook EW, Lindsey E, Kaye D. Treatment of chronic typhoid carriers with ampicillin. *Antimicrobial agents and chemotherapy*. 1973; 3(3):439–40. <https://doi.org/10.1128/aac.3.3.439> PMID: 4597723
11. Nolan CM, White PC Jr. Treatment of typhoid carriers with amoxicillin. *Correlates of successful therapy*. *Jama*. 1978; 239(22):2352–4. <https://doi.org/10.1001/jama.239.22.2352> PMID: 642172

12. Brodie J, Macqueen IA, Livingstone D. Effect of trimethoprim-sulphamethoxazole on typhoid and salmonella carriers. *Br Med J*. 1970; 3(5718):318–9. <https://doi.org/10.1136/bmj.3.5718.318> PMID: 5451954
13. Ristori C, Rodriguez H, Vicent P, Ferreccio C, Garcia J, Lobos H, et al. Persistence of the *Salmonella* typhi-paratyphi carrier state after gallbladder removal. *Bull Pan Am Health Organ*. 1982; 16(4):361–6. PMID: 7165819
14. Crawford RW, Rosales-Reyes R, Ramirez-Aguilar Mde L, Chapa-Azuela O, Alpuche-Aranda C, Gunn JS. Gallstones play a significant role in *Salmonella* spp. gallbladder colonization and carriage. *Proceedings of the National Academy of Sciences of the United States of America*. 2010; 107(9):4353–8. <https://doi.org/10.1073/pnas.1000862107> PMID: 20176950
15. Prouty AM, Schwesinger WH, Gunn JS. Biofilm formation and interaction with the surfaces of gallstones by *Salmonella* spp. *Infection and immunity*. 2002; 70(5):2640–9. <https://doi.org/10.1128/iai.70.5.2640-2649.2002> PMID: 11953406
16. Flemming HC, Wingender J. The biofilm matrix. *Nature reviews Microbiology*. 2010; 8(9):623–33. <https://doi.org/10.1038/nrmicro2415> PMID: 20676145
17. Costerton JW, Lewandowski Z, Caldwell DE, Korber DR, Lappin-Scott HM. Microbial biofilms. *Annu Rev Microbiol*. 1995; 49:711–45. <https://doi.org/10.1146/annurev.mi.49.100195.003431> PMID: 8561477
18. Gonzalez JF, Alberts H, Lee J, Doolittle L, Gunn JS. Biofilm Formation Protects *Salmonella* from the Antibiotic Ciprofloxacin In Vitro and In Vivo in the Mouse Model of chronic Carriage. *Scientific reports*. 2018; 8(1):222. <https://doi.org/10.1038/s41598-017-18516-2> PMID: 29317704
19. Gunn JS, Bakaletz LO, Wozniak DJ. What's on the Outside Matters: The Role of the Extracellular Polymeric Substance of Gram-negative Biofilms in Evading Host Immunity and as a Target for Therapeutic Intervention. *The Journal of biological chemistry*. 2016; 291(24):12538–46. <https://doi.org/10.1074/jbc.R115.707547> PMID: 27129225
20. Adcox HE, Vasicek EM, Dwivedi V, Hoang KV, Turner J, Gunn JS. *Salmonella* Extracellular Matrix Components Influence Biofilm Formation and Gallbladder Colonization. *Infection and immunity*. 2016; 84(11):3243–51. <https://doi.org/10.1128/IAI.00532-16> PMID: 27600501
21. Goodman SD, Obergfell KP, Jurcisek JA, Novotny LA, Downey JS, Ayala EA, et al. Biofilms can be dispersed by focusing the immune system on a common family of bacterial nucleoid-associated proteins. *Mucosal immunology*. 2011; 4(6):625–37. <https://doi.org/10.1038/mi.2011.27> PMID: 21716265
22. Novotny LA, Amer AO, Brockson ME, Goodman SD, Bakaletz LO. Structural stability of *Burkholderia cenocepacia* biofilms is reliant on eDNA structure and presence of a bacterial nucleic acid binding protein. *PLoS One*. 2013; 8(6):e67629. <https://doi.org/10.1371/journal.pone.0067629> PMID: 23799151
23. Idicula WA, Jursicek JA, Cass ND, Ali S, Goodman SD, Elmaraghy CA, et al. Identification of biofilms in post-tympanostomy tube otorrhea. *Laryngoscope*. 2016; In Press. <https://doi.org/10.1002/lary.25826> PMID: 27426942
24. Devaraj A, Buzzo JR, Mashburn-Warren L, Gloag ES, Novotny LA, Stoodley P, et al. The extracellular DNA lattice of bacterial biofilms is structurally related to Holliday junction recombination intermediates. *Proceedings of the National Academy of Sciences of the United States of America*. 2019. <https://doi.org/10.1073/pnas.1909017116> PMID: 31767757
25. Brandstetter KA, Jurcisek JA, Goodman SD, Bakaletz LO, Das S. Antibodies directed against integration host factor mediate biofilm clearance from nasopore. *The Laryngoscope*. 2013; 123(11):2626–32. <https://doi.org/10.1002/lary.24183> PMID: 23670606
26. Rocco CJ, Davey ME, Bakaletz LO, Goodman SD. Natural antigenic differences in the functionally equivalent extracellular DNABII proteins of bacterial biofilms provide a means for targeted biofilm therapeutics. *Molecular oral microbiology*. 2016. <https://doi.org/10.1111/omi.12157> PMID: 26988714
27. Novotny LA, Jurcisek JA, Goodman SD, Bakaletz LO. Monoclonal antibodies against DNA-binding tips of DNABII proteins disrupt biofilms in vitro and induce bacterial clearance in vivo. *EBioMedicine*. 2016; 10:33–44. <https://doi.org/10.1016/j.ebiom.2016.06.022> PMID: 27342872
28. Freire MO, Devaraj A, Young A, Navarro JB, Downey JS, Chen C, et al. A Bacterial Biofilm Induced Oral Osteolytic Infection Can be Successfully Treated by Immuno-Targeting an Extracellular Nucleoid Associated Protein. *Molecular oral microbiology*. 2016. <https://doi.org/10.1111/omi.12155> PMID: 26931773
29. Devaraj A, Buzzo J, Rocco CJ, Bakaletz LO, Goodman SD. The DNABII family of proteins is comprised of the only nucleoid associated proteins required for nontypeable *Haemophilus influenzae* biofilm structure. *MicrobiologyOpen*. 2017. <https://doi.org/10.1002/mbo3.563> PMID: 29230970
30. Novotny LA, Goodman SD, Bakaletz LO. Redirecting the immune response towards immunoprotective domains of a DNABII protein resolves experimental otitis media. *NPJ Vaccines*. 2019; 4:43. <https://doi.org/10.1038/s41541-019-0137-1> PMID: 31632744

31. Wong VK, Baker S, Pickard DJ, Parkhill J, Page AJ, Feasey NA, et al. Phylogeographical analysis of the dominant multidrug-resistant H58 clade of *Salmonella* Typhi identifies inter- and intracontinental transmission events. *Nat Genet.* 2015; 47(6):632–9. <https://doi.org/10.1038/ng.3281> PMID: 25961941
32. Wong VK, Baker S, Connor TR, Pickard D, Page AJ, Dave J, et al. An extended genotyping framework for *Salmonella enterica* serovar Typhi, the cause of human typhoid. *Nat Commun.* 2016; 7:12827. <https://doi.org/10.1038/ncomms12827> PMID: 27703135
33. Santander J, Wanda SY, Nickerson CA, Curtiss R. Role of RpoS in fine-tuning the synthesis of Vi capsular polysaccharide in *Salmonella enterica* serotype Typhi. *Infection and immunity.* 2007; 75(3):1382–92. <https://doi.org/10.1128/IAI.00888-06> PMID: 17178790
34. Virlogeux I, Waxin H, Ecobichon C, Popoff MY. Role of the *viaB* locus in synthesis, transport and expression of *Salmonella typhi* Vi antigen. *Microbiology (Reading).* 1995; 141 (Pt 12):3039–47. <https://doi.org/10.1099/13500872-141-12-3039> PMID: 8574397
35. Gustave JE, Jurcisek JA, McCoy KS, Goodman SD, Bakaletz LO. Targeting bacterial integration host factor to disrupt biofilms associated with cystic fibrosis. *Journal of cystic fibrosis: official journal of the European Cystic Fibrosis Society.* 2013; 12(4):384–9. <https://doi.org/10.1016/j.jcf.2012.10.011> PMID: 23168017
36. Brockson ME, Novotny LA, Mokrzan EM, Malhotra S, Jurcisek JA, Akbar R, et al. Evaluation of the kinetics and mechanism of action of anti-integration host factor-mediated disruption of bacterial biofilms. *Molecular microbiology.* 2014; 93(6):1246–58. <https://doi.org/10.1111/mmi.12735> PMID: 25069521
37. Freire MO, Devaraj A, Young A, Navarro JB, Downey JS, Chen C, et al. A bacterial-biofilm-induced oral osteolytic infection can be successfully treated by immuno-targeting an extracellular nucleoid-associated protein. *Molecular oral microbiology.* 2017; 32(1):74–88. <https://doi.org/10.1111/omi.12155> PMID: 26931773
38. Matthews TD, Rabsch W, Maloy S. Chromosomal rearrangements in *Salmonella enterica* serovar Typhi strains isolated from asymptomatic human carriers. *mBio.* 2011; 2(3):e00060–11. <https://doi.org/10.1128/mBio.00060-11> PMID: 21652779
39. Marzel A, Desai PT, Goren A, Schorr YI, Nissan I, Porwollik S, et al. Persistent Infections by Nontyphoidal *Salmonella* in Humans: Epidemiology and Genetics. *Clinical infectious diseases: an official publication of the Infectious Diseases Society of America.* 2016; 62(7):879–86. <https://doi.org/10.1093/cid/civ1221> PMID: 26740515
40. Van Acker H, Coenye T. The Role of Efflux and Physiological Adaptation in Biofilm Tolerance and Resistance. *The Journal of biological chemistry.* 2016; 291(24):12565–72. <https://doi.org/10.1074/jbc.R115.707257> PMID: 27129224
41. Whitchurch CB, Tolker-Nielsen T, Ragas PC, Mattick JS. Extracellular DNA required for bacterial biofilm formation. *Science.* 2002; 295(5559):1487. <https://doi.org/10.1126/science.295.5559.1487> PMID: 11859186
42. Tang L, Schramm A, Neu TR, Revsbech NP, Meyer RL. Extracellular DNA in adhesion and biofilm formation of four environmental isolates: a quantitative study. *FEMS Microbiol Ecol.* 2013; 86(3):394–403. <https://doi.org/10.1111/1574-6941.12168> PMID: 23786537
43. Vilain S, Pretorius JM, Theron J, Brozel VS. DNA as an adhesin: *Bacillus cereus* requires extracellular DNA to form biofilms. *Applied and environmental microbiology.* 2009; 75(9):2861–8. <https://doi.org/10.1128/AEM.01317-08> PMID: 19251901
44. Qin Z, Ou Y, Yang L, Zhu Y, Tolker-Nielsen T, Molin S, et al. Role of autolysin-mediated DNA release in biofilm formation of *Staphylococcus epidermidis*. *Microbiology.* 2007; 153(Pt 7):2083–92. <https://doi.org/10.1099/mic.0.2007/006031-0> PMID: 17600053
45. Johnson L, Horsman SR, Charron-Mazenod L, Turnbull AL, Mulcahy H, Surette MG, et al. Extracellular DNA-induced antimicrobial peptide resistance in *Salmonella enterica* serovar Typhimurium. *BMC Microbiol.* 2013; 13:115. <https://doi.org/10.1186/1471-2180-13-115> PMID: 23705831
46. Charles RC, Sultana T, Alam MM, Yu Y, Wu-Freeman Y, Bufano MK, et al. Identification of immunogenic *Salmonella enterica* serotype Typhi antigens expressed in chronic biliary carriers of *S. Typhi* in Kathmandu, Nepal. *PLoS Negl Trop Dis.* 2013; 7(8):e2335. <https://doi.org/10.1371/journal.pntd.0002335> PMID: 23936575
47. Nagy TA, Moreland SM, Andrews-Polymeris H, Detweiler CS. The ferric enterobactin transporter Fep is required for persistent *Salmonella enterica* serovar typhimurium infection. *Infection and immunity.* 2013; 81(11):4063–70. <https://doi.org/10.1128/IAI.00412-13> PMID: 23959718
48. Takatsuka M, Osada-Oka M, Satoh EF, Kitadokoro K, Nishiuchi Y, Niki M, et al. A histone-like protein of mycobacteria possesses ferritin superfamily protein-like activity and protects against DNA damage by Fenton reaction. *PLoS One.* 2011; 6(6):e20985. <https://doi.org/10.1371/journal.pone.0020985> PMID: 21698192

49. Crawford RW, Gibson DL, Kay WW, Gunn JS. Identification of a bile-induced exopolysaccharide required for *Salmonella* biofilm formation on gallstone surfaces. *Infection and immunity*. 2008; 76(11):5341–9. <https://doi.org/10.1128/IAI.00786-08> PMID: 18794278
50. Gonzalez JF, Tucker L, Fitch J, Wetzell A, White P, Gunn JS. Human Bile-Mediated Regulation of *Salmonella* Curli Fimbriae. *Journal of bacteriology*. 2019; 201(18). <https://doi.org/10.1128/JB.00055-19> PMID: 30936374
51. Gibson DL, White AP, Snyder SD, Martin S, Heiss C, Azadi P, et al. *Salmonella* produces an O-antigen capsule regulated by AgfD and important for environmental persistence. *Journal of bacteriology*. 2006; 188(22):7722–30. <https://doi.org/10.1128/JB.00809-06> PMID: 17079680
52. Romling U, Bokranz W, Rabsch W, Zogaj X, Nimtz M, Tschape H. Occurrence and regulation of the multicellular morphotype in *Salmonella* serovars important in human disease. *Int J Med Microbiol*. 2003; 293(4):273–85. <https://doi.org/10.1078/1438-4221-00268> PMID: 14503792
53. Evans ML, Chapman MR. Curli biogenesis: order out of disorder. *Biochimica et biophysica acta*. 2014; 1843(8):1551–8. <https://doi.org/10.1016/j.bbamcr.2013.09.010> PMID: 24080089
54. Rice PA, Yang S, Mizuuchi K, Nash HA. Crystal structure of an IHF-DNA complex: a protein-induced DNA U-turn. *Cell*. 1996; 87(7):1295–306. [https://doi.org/10.1016/s0092-8674\(00\)81824-3](https://doi.org/10.1016/s0092-8674(00)81824-3) PMID: 8980235
55. Kamashev D, Rouviere-Yaniv J. The histone-like protein HU binds specifically to DNA recombination and repair intermediates. *The EMBO journal*. 2000; 19(23):6527–35. <https://doi.org/10.1093/emboj/19.23.6527> PMID: 11101525
56. Browning DF, Grainger DC, Busby SJ. Effects of nucleoid-associated proteins on bacterial chromosome structure and gene expression. *Current opinion in microbiology*. 2010; 13(6):773–80. <https://doi.org/10.1016/j.mib.2010.09.013> PMID: 20951079
57. Devaraj A, Justice SS, Bakaletz LO, Goodman SD. DNABII proteins play a central role in UPEC biofilm structure. *Molecular microbiology*. 2015; 96(6):1119–35. <https://doi.org/10.1111/mmi.12994> PMID: 25757804
58. Justice SS, Li B, Downey JS, Dabdoub SM, Brockson ME, Probst GD, et al. Aberrant community architecture and attenuated persistence of uropathogenic *Escherichia coli* in the absence of individual IHF subunits. *PLoS One*. 2012; 7(10):e48349. <https://doi.org/10.1371/journal.pone.0048349> PMID: 23133584
59. Datsenko KA, Wanner BL. One-step inactivation of chromosomal genes in *Escherichia coli* K-12 using PCR products. *Proceedings of the National Academy of Sciences of the United States of America*. 2000; 97(12):6640–5. <https://doi.org/10.1073/pnas.120163297> PMID: 10829079
60. Cherepanov PP, Wackernagel W. Gene disruption in *Escherichia coli*: TcR and KmR cassettes with the option of Flp-catalyzed excision of the antibiotic-resistance determinant. *Gene*. 1995; 158(1):9–14. [https://doi.org/10.1016/0378-1119\(95\)00193-a](https://doi.org/10.1016/0378-1119(95)00193-a) PMID: 7789817
61. Branchu P, Charity OJ, Bawn M, Thilliez G, Dallman TJ, Petrovska L, et al. SGI-4 in Monophasic *Salmonella* Typhimurium ST34 Is a Novel ICE That Enhances Resistance to Copper. *Front Microbiol*. 2019; 10:1118. <https://doi.org/10.3389/fmicb.2019.01118> PMID: 31178839
62. Stamatakis A. RAxML-VI-HPC: maximum likelihood-based phylogenetic analyses with thousands of taxa and mixed models. *Bioinformatics*. 2006; 22(21):2688–90. <https://doi.org/10.1093/bioinformatics/btl446> PMID: 16928733
63. Heydorn A, Ersboll BK, Hentzer M, Parsek MR, Givskov M, Molin S. Experimental reproducibility in flow-chamber biofilms. *Microbiology*. 2000; 146(Pt 10):2409–15. <https://doi.org/10.1099/00221287-146-10-2409> PMID: 11021917